Head-to-head · Value Score
bmiMD vs Eve
Two GLP-1 deals, scored on the same six factors. bmiMD lands a Value Score of 89, Eve a 63. Here's who gives you the honest lower price — and where each one bites back.
bmiMD
#11 · Grade A · Great Deal
Est. first month
$99/mo
Save ~93% vs brand-nameEve
#333 · Grade C · Watch List
Est. first month
From $195/mo (compounded)
Save ~86% vs brand-nameThe verdict
bmiMD takes it on Value Score, 89 to 63 — an est. $99/mo first month, with no teaser step-up baked in. Eve isn't out of it: Shoppers who want women's-health GLP-1 with compounded or brand-name access.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | bmiMD | Eve |
|---|---|---|
| Value Score | 89 (A) | 63 (C) |
| Est. first month | $99/mo | From $195/mo (compounded) |
| Save vs brand-name | ~93% | ~86% |
| Semaglutide | $99/mo | From $195/mo (compounded) |
| Tirzepatide | $139/mo | From $195/mo (compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
bmiMD
Sub-$100 semaglutide and a low $139 tirzepatide, flat and nationwide — a straight-up low-price play.
Why it's a deal
- $99 flat semaglutide and a low $139 tirzepatide
- Available in all 50 states
- Both molecules priced up front
The fine print
- Not LegitScript-certified — do your own pharmacy diligence
- Thin public track record; no oral or brand-name option
Eve
Eve is a women's-health-focused GLP-1 telehealth platform — distinctive positioning in a largely gender-neutral market — offering both compounded semaglutide and tirzepatide (including an oral sublingual…
Why it's a deal
- Genuinely women's-health-focused — fills a real gap among gender-neutral GLP-1 competitors
- Both compounded and brand-name FDA-approved options (Wegovy/Ozempic/Mounjaro) on one platform — rare
- LegitScript Certified with a verifiable ID
- Publishes the FDA compounded-medication disclaimer
- Oral sublingual semaglutide offered alongside injectable
The fine print
- Full states-served list not disclosed publicly
- 503A pharmacy partner not named, and 503A vs 503B status not specified
- Named medical director / clinical leadership not disclosed
- Corporate legal entity not disclosed
- Governing law / arbitration venue not stated
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores bmiMD is ranked on the bmiMD alternatives board, and the same list for the other side is on alternatives to Eve.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.